Literature DB >> 3965239

Distribution of alpha interferon in serum and cerebrospinal fluid after systemic administration.

R A Smith, F Norris, D Palmer, L Bernhardt, R J Wills.   

Abstract

After intravenous infusion of recombinant leukocyte interferon (rIFN-alpha A) to four subjects with an indwelling reservoir, serial serum and cerebrospinal fluid samples were taken over 48 hr and were analyzed for interferon by an enzyme immunoassay method (ELISA). On separate occasions, 18 and 50 X 10(6) of rIFN-alpha A were infused over 10 min. Maximum serum concentrations of rIFN-alpha A ranged from 6720 to 11,000 pg/ml and from 32,900 to 43,400 pg/ml after the 18 and 50 X 10(6) U doses. There was no measurable concentration of rIFN-alpha A in the cerebrospinal fluid of subjects who received 18 X 10(6) U doses. In three of four subjects who received 50 X 10(6) U rIFN-alpha A, concentrations ranged from 17 to 70 pg/ml that were measurable no earlier than 1 hr after the start of the infusion and that in two cases were measurable throughout 24 hr.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3965239     DOI: 10.1038/clpt.1985.16

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  19 in total

1.  Interferon- alpha and - beta restrict polyomavirus JC replication in primary human fetal glial cells: implications for progressive multifocal leukoencephalopathy therapy.

Authors:  Juliene K G Co; Saguna Verma; Ulziijargal Gurjav; Laarni Sumibcay; Vivek R Nerurkar
Journal:  J Infect Dis       Date:  2007-07-20       Impact factor: 5.226

Review 2.  Clinical pharmacokinetics of interferons.

Authors:  R J Wills
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 3.  Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise.

Authors:  Jennifer C Felger; Andrew H Miller
Journal:  Front Neuroendocrinol       Date:  2012-09-21       Impact factor: 8.606

4.  Negative regulation of human astrocytes by interferon (IFN) α in relation to growth inhibition and impaired glucose utilization.

Authors:  Ting Wang; Yasuhiro Takikawa; Kei Sawara; Yuichi Yoshida; Kazuyuki Suzuki
Journal:  Neurochem Res       Date:  2012-05-25       Impact factor: 3.996

5.  Intraventricular interferon in a case of subacute sclerosing panencephalitis.

Authors:  A Boiardi; S M Baldini; A Sghirlanzoni; R Mancuso; F Corridori
Journal:  Ital J Neurol Sci       Date:  1987-06

6.  Involvement of central opioid systems in human interferon-alpha induced immobility in the mouse forced swimming test.

Authors:  M Makino; Y Kitano; C Komiyama; M Hirohashi; K Takasuna
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

7.  A pharmacokinetic model for alpha interferon administered subcutaneously.

Authors:  E Chatelut; L Rostaing; N Grégoire; J L Payen; A Pujol; J Izopet; G Houin; P Canal
Journal:  Br J Clin Pharmacol       Date:  1999-04       Impact factor: 4.335

Review 8.  Interferon-alpha in malignant and viral diseases. A review.

Authors:  R T Dorr
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

Review 9.  Interferon-alpha-2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis.

Authors:  M Haria; P Benfield
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546

Review 10.  Interferons in multiple sclerosis. A review of the evidence.

Authors:  H S Panitch
Journal:  Drugs       Date:  1992-12       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.